All In Biotech

NDA 204275 · Glaxo Grp LTD

Breo Ellipta

Fluticasone Furoate, Vilanterol Trifenatate · Inhalation

Novel

Last checked: Nov 19, 2026Latest source record: May 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

May 10, 2013

Approved uses

4

Original approval plus efficacy supplements

Registered trials

737

240 Phase 3, 19 recruiting

FAERS reports

36,211

15,062 serious, 1,485 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 21, 2024.

Fluticasone Furoate/Vilanterol ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long‑acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 5 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 ) 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease Fluticasone Furoate/Vilanterol ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). 1.2 Maintenance Treatment of Asthma Fluticasone Furoate/Vilanterol ELLIPTA is indicated for the maintenance treatment of asthma in patients aged 5 years and older. 1.3 Limitations of Use Fluticasone Furoate/Vilanterol ELLIPTA is NOT indicated for the relief of acute bronchospasm.

Mechanism: Fluticasone Furoate/Vilanterol ELLIPTA Fluticasone Furoate/Vilanterol ELLIPTA contains both fluticasone furoate and vilanterol. The mechanisms of action described below for the individual components apply to Fluticasone Furoate/Vilanterol ELLIPTA. These drugs represent 2 different classes of medications (an ICS and a LABA), each having different effects on clinical and physiological indices. Fluticasone Furoate Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 12, 2023 Supplement 22 · Efficacy · priority review LetterLabel
  • May 15, 2017 Supplement 12 · Efficacy LabelLetter
  • Apr 30, 2015 Supplement 1 · Efficacy LabelLetter
  • May 10, 2013 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
3 products under this application
  • BREO ELLIPTA · FLUTICASONE FUROATE 0.2MG/INH; VILANTEROL TRIFENATATE EQ 0.025MG BASE/INH · POWDER, INHALATION · Prescription
  • BREO ELLIPTA · FLUTICASONE FUROATE 0.05MG/INH; VILANTEROL TRIFENATATE EQ 0.025MG BASE/INH · POWDER, INHALATION · Prescription
  • BREO ELLIPTA · FLUTICASONE FUROATE 0.1MG/INH; VILANTEROL TRIFENATATE EQ 0.025MG BASE/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Furoate" as an intervention, any sponsor and status, largest first.

All 737 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea6,235
  • drug ineffective4,089
  • asthma4,061
  • cough3,458
  • wheezing2,688
  • wrong technique in device usage process2,341
  • pneumonia2,247
  • product complaint1,882
  • product dose omission issue1,827
  • fatigue1,769
  • off label use1,587
  • therapeutic product effect incomplete1,553

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
20112
20126
201314
2014738
20151,546
20162,738
20173,448
20184,039
20194,379
20204,480
20213,696
20222,734
20232,424
20242,390
20252,136
20261,439

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Breo Ellipta (Fluticasone/Vilanterol)

2024 spending

$1.36B

Beneficiaries

596,052

2,617,269 claims

Per beneficiary

$2,283

$6.50 per unit

View as table
YearSpending
2020$1,504,155,910
2021$1,523,303,704
2022$1,427,824,950
2023$1,373,600,714
2024$1,360,528,641

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 243 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.